Company profile: Ayala Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage small molecule therapeutics, including gamma secretase inhibitors that block Notch-pathway activation. Pipeline includes AL101 in Phase 2 for recurrent/metastatic adenoid cystic carcinoma and AL102 in Phase 2/3 for desmoid tumors, with a planned Phase 2 in relapsed/refractory T-cell acute lymphoblastic leukemia. Conducts clinical trials to evaluate safety and efficacy.
Products and services
- Gamma Secretase Inhibitors: Notch-pathway-targeted drugs that inhibit pathway activation, directly addressing underlying drivers of tumor growth across various cancers
- AL102: Phase 2/3-stage candidate developed to treat progressing desmoid tumors, with a planned Phase 2 study in relapsed/refractory T-cell acute lymphoblastic leukemia
- AL101: GSI-class candidate in Phase 2 trials for recurrent/metastatic adenoid cystic carcinoma, inhibiting gamma secretase to block Notch-pathway activation driving tumor growth
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ayala Pharmaceuticals
Precirix
HQ: Belgium
Website
- Description: Provider of radio-immunotherapeutic drugs for cancer patients, developing single-domain antibody CAM-H2 targeting HER2 combined with iodine-131 in Phase I/II for HER2-positive metastatic breast, gastric, and gastroesophageal cancers; FAP-targeting radiopharmaceutical program entering clinical trials; and a theranostic approach using imaging to select patients before treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precirix company profile →
AltruBio
HQ: United States
Website
- Description: Provider of targeted antibody therapeutics for cancer and immune related inflammatory diseases, including ALTB-168, a humanized antibody targeting late-stage, chronically activated T cells with clinical efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and acute graft versus host disease, and ALTB-268, a second-generation antibody in trials for ulcerative colitis and psoriatic arthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AltruBio company profile →
Eclipse Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics discovery and development targeting cancer stem cells (CSCs) and other innovative cancer treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eclipse Therapeutics company profile →
Biovica
HQ: Sweden
Website
- Description: Provider of blood-based biomarker assays to help oncologists monitor cancer progression, including the DiviTum® TKa Test measuring cell proliferation from solid tumors, and pharma services offering TKa testing for dose-response information, patient selection, and treatment monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biovica company profile →
OctreoPharm Sciences
HQ: Germany
Website
- Description: Provider of radiopharmaceuticals and theranostic solutions for neuroendocrine tumors, including OPS201, a peptide for PRRT with 90Yttrium or 177Lutetium, and OPS202, a 68Gallium-labeled PET imaging agent targeting somatostatin receptors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OctreoPharm Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ayala Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ayala Pharmaceuticals
2.2 - Growth funds investing in similar companies to Ayala Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ayala Pharmaceuticals
4.2 - Public trading comparable groups for Ayala Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →